Replies to post #224877 on Biotech Values

[mcbio]

(ASMB)—ENTA’s CEO, Jay Luly just said that ASMB’s HBV core inhibitor is probably too weak, based on data presented at EASL (in so many words).

Judging by ASMB's own actions via the development of much more potent follow-on versions, I'd say they likely agree. ; )